ArticleIn silico pharmacology2025

Naringenin and its structural analogues inhibit CDK2: a combined MD-MMGBSA and protein-ligand interaction study for colon cancer.

Francis Dhiya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.